

Continuing Education Credit Information

Course Description

This one-day symposium will update participants on recent advances in the diagnosis and treatment of patients with localized and advanced prostate cancer. Expert faculty will deliver state-of-the-art lectures that will include treatment approaches, clinical trials, biologic and genomic factors and future directions. Attendees will have ample time to network with leaders in the field, participate in panel discussions and navigate complicated cases. Key clinical topics will include the use of biomarkers and modern imaging technologies in the management of early stage prostate cancer as well as advances in the multidisciplinary approach to patients with high-risk, locally advanced, relapsed non-metastatic, and metastatic prostate cancer. Applications of new therapeutic agents, cutting edge radiation technology, combined modality strategies and evolving minimally invasive urologic surgical approaches will also be discussed. In addition, recommendations on resources for patients and practicing healthcare providers will be shared including specialized centers of excellence and research, advocacy and special organizational resources in the region. Ample time will be provided during and between sessions for Q & A and meeting with speakers and experts.

Learning Objectives

Physicians

- Interpret prostate MRIs in developing treatment strategies for organ-confined prostate cancer
- Interpret prostate biomarkers in planning treatment for organ-confined prostate cancer
- Recognize intermediate and high-risk patients who will benefit from brachytherapy
- Identify intermediate and high-risk patients who will benefit from immunotherapy
- Recognize intermediate and high-risk patients who will benefit from salvage therapy
- Distinguish the proper use of early chemohormonal therapy in patients with high-risk and metastatic prostate cancer
- Recognize intermediate and high-risk patients who will benefit from chemotherapy
- Recognize intermediate and high-risk patients who will benefit from testosterone replacement
- Illustrate the benefits of genetic testing for risk stratification in organ-confined prostate cancer
- Assess the latest guidelines of the National Comprehensive Cancer Network (NCCN)

Nurses

- Educate patients and family on the risk, benefits, and peri-procedural management of transperineal biopsy, rectal spacer placement, and retzius-sparing prostatectomy
- Recognize the different clinical states of advanced prostate cancer (M0, oligometastatic, widely metastatic) and the relevant treatment options for each state
- Identify the application of genomic testing of tumors in selecting newly approved systemic therapeutic agents

Pharmacists

- Identify the diagnostic, prognostic, and monitoring tests for a patient with prostate cancer
- Explain the different treatment modalities, including surgery, hormonal therapy, chemotherapy, immunotherapy, and radiotherapy, for patients with prostate cancer
- Discuss the current and emerging treatment options in the management of patients with castration resistant prostate cancer
- Discuss how to manage potential side effects to patients on hormonal therapy for prostate cancer

Target Audience

This conference is intended for urologists, radiation and medical oncologists, oncologic surgeons, nuclear medicine technologists, residents, fellows, physician assistants, nurse practitioners, nurses, pharmacists, physical therapists and other allied healthcare professionals interested in the treatment and management of prostate cancer.

CE Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



This activity was planned by and for the healthcare team, and learners will receive 7.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Direct continuing education credits will be awarded to the following: physicians, nurses, and pharmacists.

Advances in
**PROSTATE
CANCER 2020**

March 28, 2020
The Wink Hotel
Washington, D.C.

MedStar Health
3007 Tilden St., NW, Suite 3N
Washington, DC 20008



For more information and to register, please visit
CE.MedStarHealth.org/Prostate

Advances in PROSTATE CANCER 2020



March 28, 2020 | The Wink Hotel | Washington, D.C.

COURSE DIRECTORS

Keith J. Kowalczyk, MD
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Washington, D.C.

Ross E. Krasnow, MD, MPH
MedStar Washington Hospital Center
Washington, D.C.

Young Kwok, MD
University of Maryland Medical Center
Baltimore, MD

George K. Phillips, MBBS, MD, MPH
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.



Course Directors

Keith J. Kowalczyk, MD
Co-Director, Urologic Oncology
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Associate Professor, Urology
Georgetown University School of Medicine
Washington, D.C.

Ross E. Krasnow, MD, MPH
Staff Physician, Urologic Oncology
MedStar Washington Hospital Center
Washington, D.C.

Faculty

KEYNOTE SPEAKER

Todd M. Morgan, MD
Chief, Division of Urologic Onocology
Associate Professor, Urology
University of Michigan
Ann Arbor, MI

Emmanuel Antonarakis, MD
Professor, Oncology and Urology
Sidney Kimmel Comprehensive
Cancer Center
The Johns Hopkins University
Baltimore, MD

Jeanny B. Aragon-Ching, MD
Clinical Program Director,
Genitourinary Cancers
Inova Schar Cancer Institute
Fairfax, VA
Associate Professor, Medicine
Virginia Commonwealth University
Richmond, VA

Robert Dreicer, MD, MS, MACP, FASCO
Deputy Director, UVA Cancer Center
Section Head Medical Oncology
Professor, Medicine and Urology
University of Virginia
Charlottesville, VA

Behfar Ehdaie, MD, MPH
Surgeon, Urology
Memorial Sloan Kettering Cancer Center
New York, NY

Khang Ho, PharmD, BCOP
Oncology & Investigational Drug
Services Manager
MedStar Georgetown University Hospital
Washington, D.C.

Young Kwok, MD
Maryland Proton Treatment Center
University of Maryland Medical Center
Associate Professor, Radiation Oncology
University of Maryland School of Medicine
Baltimore, MD

George K. Philips, MBBS, MD, MPH
Vice Chair, Department of Medicine
Staff Physician, Division of Hematology/Oncology
MedStar Washington Hospital Center
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.

Jim C. Hu, MD, MPH
Attending Urologist
New York Presbyterian/Weill Cornell
Director of the LeFrak Center for
Robotic Surgery
Ronald P. Lynch Professor of
Urologic Oncology
Weill Cornell Medicine
New York, NY

Fatima Karzai, MD
Assistant Research Physician
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
Bethesda, MD

Isaac Yi Kim, MD, PhD, MBA
Professor and Chief
Division of Urology
Rutgers Robert Wood Johnson
Medical School
Chief, Section of Urologic Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Jianqing Lin, MD
Medical Oncologist, Hematology/Oncology
Co-Program Leader, GU Oncology
George Washington Cancer Center
Associate Professor, Medicine
George Washington School of Medicine &
Health Sciences
Washington, D.C.

Ravi A. Madan, MD
Clinical Director
Genitourinary Malignancies Branch
National Cancer Institute
Bethesda, MD

Channing J. Paller, MD
Medical Oncologist
The Johns Hopkins University
Associate Professor, Oncology
Sidney Kimmel Comprehensive
Cancer Center
Baltimore, MD

Peter A. Pinto, MD
Director, Urologic Oncology
Fellowship Program
Head, Prostate Cancer Section
Investigator, Urologic Oncology Branch
National Cancer Institute
Bethesda, MD

Benjamin T. Ristau, MD, MHA
Surgical Director of Urologic Oncology
Assistant Professor, Surgery
UConn Health
Farmington, CT

Daniel Spratt, MD
Director, Spine Oncology Program
Chair, Genitourinary Clinical Research
Rogel Cancer Center
Associate Professor
Laurie Snow Research Professor,
Radiation Oncology
University of Michigan
Ann Arbor, MI

Daniel Suzman, MD
Acting Team Lead
Genitourinary Malignancies Team
Office of Hematology and Oncology Products
U.S. Food and Drug Administration
Silver Spring, MD

Agenda

7:00 a.m. Registration and Continental Breakfast

7:30 a.m. Introduction
Ross E. Krasnow, MD, MPH

SESSION I: Early Prostate Cancer
Moderators: Keith J. Kowalczyk, MD; Ross E. Krasnow, MD, MPH

7:45 a.m. Transperineal Prostate Biopsy
Benjamin T. Ristau, MD, MHA

8:10 a.m. Active Surveillance in Intermediate-Risk Prostate Cancer
Behfar Ehdaie, MD, MPH

8:35 a.m. Imaging in the Pretreatment Setting
Peter A. Pinto, MD

9:00 a.m. Emerging Role of Focal Therapy for Localized Prostate Cancer
Jim C. Hu, MD, MPH

9:25 a.m. Retzius Sparing Robotic Prostatectomy: Evolution of Technique and Initial Outcomes
Keith J. Kowalczyk, MD

9:55 a.m. Break and Visit the Exhibits

10:15 a.m. Role of Radical Prostatectomy in Men with Oligometastatic Prostate Cancer
Isaac Yi Kim, MD, PhD, MBA

10:40 a.m. Personalized Approach to Postoperative Radiation and Hormonal Therapy in Men with Biochemical Recurrence Following Prostatectomy
Daniel Spratt, MD

11:05 a.m. Questions and Discussion
Moderators: Keith Kowalczyk, MD; Ross E. Krasnow, MD, MPH
Panelists: B. Ehdaie, J. Hu, I. Kim, B. Ristau, P. Pinto, D. Spratt

KEYNOTE LECTURE

Prostate Cancer Genomics: Where are We and Where are We Going?
Todd M. Morgan, MD

12:30 p.m. Lunch and Visit the Exhibits

SESSION II: Advanced Prostate Cancer
Moderator: Jianqing Lin, MD

1:30 p.m. Early Radiation in the Oligometastatic and Salvage Settings
Young Kwok, MD

1:50 p.m. Biochemical Failure
Channing Paller, MD
Ravi A. Madan, MD

2:15 p.m. Genomics of Advanced Prostate Cancer and its Clinical Relevance
Emmanuel Antonarakis, MD

2:35 p.m. PARP Inhibitors and PARPi Combination Strategies
Fatima Karzai, MD

2:40 p.m. Metastatic CRPC: Making Practical Sense of New Choices and Evolving Issues
George K. Philips, MBBS, MD, MPH

2:55 p.m. Non-Metastatic Castration Resistant Prostate Cancer
Jeanny B. Aragon-Ching, MD; Daniel Suzman, MD

3:15 p.m. Metastatic Castration Resistant Prostate Cancer
Robert Dreicer, MD, MS, MACP, FASCO

3:25 p.m. Questions and Discussion
Moderators: Young Kwok, MD; George K. Philips, MBBS, MD, MPH
Panelists: E. Antonarakis, J. Aragon-Ching, R. Dreicer, F. Karzai, R. Madan, C. Paller, D. Suzman

3:55 p.m. Adjourn

Registration Information

Registration Fees:	
Physician	\$150
Resident or Fellow	\$75
Physician Assistant	\$75
Nurse Practitioner	\$75
Nurse	\$75
Pharmacist	\$75
Allied Health Professional	\$75

Online Registration Preferred

Please visit our secure website at CE.MedStarHealth.org/prostate for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at MedStarCME@gmail.com or 202-780-1655.

Cancellation Policy

Cancellations made in writing by Friday, February 14, 2020 will be subject to a 50% penalty. No refunds will be given after Friday, February 14, 2020. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-780-1655 or email MedStarCME@gmail.com if you have any questions or need any additional information.

Please contact Ada Guo at ada.guo@medstar.net for information on exhibiting at this conference.

Venue Information

The Wink Hotel
1143 New Hampshire Ave. NW
Washington, D.C. 20037
202-775-0800
www.thewinkhoteldc.com

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-780-1655 to notify us of your needs.

